Table 1. Drugs under development for IBC – trials accrue patients with IBC only.

Agent (s)	IBC subtype	Phase of study	Mechanism of action targeted therapy	Clinicaltrial.gov Identification number
Ruxolitinib	TN	2	JAK/STAT TKI	NCT02041429
Paclitaxel/trastuzumab/pertuzumab	HER2 +	2	Anti-HER2 mAb	NCT01796197
Afatinib	HER2 +	2	EGFR and HER2 TKI	NCT01325428
Nintedanib	HER2 -	2	Multi TKI	NCT02389764
Dovitinib	HER2 -	2	Multi TKI	NCT01262027
Panitumumab/nab-paclitaxel/carboplatin	HER2 -	2	Anti-EGFR mAb	NCT01036087
Eribulin/doxorubicin/cyclophosphamide	HER2 -	2	–	NCT02623972
Pembrolizumab	NS	2	Anti-PD-1 mAb	NCT02411656
SU5416/doxorubicin	NS	1	VEGFR TKI	NCT00005822
Nab-paclitaxel/gemcitabine/epirubicin	NS	2	–	NCT00193206
Bevacizumab/cyclophosphamide/ 5-FU/epirubicin	NS	1	Anti-VEGF mAb	NCT01880385
Bevacizumab	NS	2	Anti-VEGF mAb	NCT00016549
Docetaxel/5-FU	NS	3	–	NCT02324088

Accessed on July 18^th 2016 at www.clinicaltrials.gov

Abbreviations: Epithelial growth factor receptor (EGFR), fluorouracil (5-FU), inflammatory breast cancer (IBC), janus kinase/ signal transducers and activators of transcription (JAK/STAT), monoclonal anti-body (mAb), receptor tyrosine-protein kinase erbB-2 (HER2), triple negative (TN), tyrosine kinase inhibitor (TKI), vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (VEGFR).